Browsing NTNU Open by Author "Sundstrøm, Stein Harald"
Now showing items 1-12 of 12
-
Behandling med neoadjuvant kjemoterapi hos kvinner med avansert brystkreft fra 2005-2021: en retrospektiv kvalitetsstudie
Frøseth, Oda Støland (Master thesis, 2022)Introduksjon: Kvinnelig brystkreft er den kreftdiagnosen som har høyest insidens på verdensbasis og neoadjuvant kjemoterapi (NACT) gis til en subgruppe av pasienter med større svulster og som har høyest risiko for ... -
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Background: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. ... -
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Fløtten, Øystein; Aasebø, Ulf (Peer reviewed; Journal article, 2013)Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved. Methods: Patients ... -
Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II
Landström, Tove; Varughese, Rosilin; Sundstrøm, Stein Harald; Torp, Sverre Helge (Journal article; Peer reviewed, 2013)Background The WHO classification system for astrocytomas is not considered optimal, mainly because of the subjective assessment of the histopathological features. Few prognostic variables have been found that stratify ... -
Major durable response of pembrolizumab in chemotherapy refractory small cell bladder cancer: A case report
Nguyen, Olav Toai Duc; Sundstrøm, Stein Harald; Westvik, Ganna Surzhykova; Røttereng, Ane Karoline Stræte; Melhus, Mona Røli; Bergseth, Cecilie; Hallem, Elisabeth Kvelstad; Røe, Oluf Dimitri (Peer reviewed; Journal article, 2020)Small cell carcinoma of the urinary bladder is a rare subtype (incidence of 1–9/1,000,000), characterized by an aggressive behavior with early metastasis and poor prognosis. Chemotherapy, radiation, and surgery are the ... -
Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
Røe, Oluf Dimitri; Szulkin, Adam; Anderssen, Endre; Flatberg, Arnar; Sandeck, Helmut; Amundsen, Tore; Erlandsen, Sten Even; Dobra, Katalin; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2012) -
Pankreaskreft. Insidens, utredning, behandling og overlevelse ved Helse Nord-Trøndelag 2010-2021
Gaupset, Lise (Master thesis, 2023)Introduksjon: Pankreaskreft er blant de mest dødelige kreftsykdommene på verdensbasis, og flesteparten av pasientene har fjernmetastaser ved diagnosetidspunktet. Få er kandidater til kirurgisk reseksjon, som er eneste ... -
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Aasebø, Ulf (Peer reviewed; Journal article, 2014)Introduction: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative ... -
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2016)Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented – probably mainly ... -
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules ... -
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Objectives Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to ... -
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Peer reviewed, 2012)Background: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective ...